Vanatius Babila Tita, DPM
Foot & Ankle Surgery · Austin, TXNPI 1114416807
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Stryker at 48.7% of the total. Reporting peaked in 2023 at $2,367 and has fallen 50.5% since, to $1,172 in 2025.
Across 102 payments — averaging $97.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$5K
- Integra Lifesciences Corporation$2K
- Treace Medical Concepts, Inc.$1K
- Rock Medical Orthopedics, Inc.$1K
- Core Surgical Group$144
- Penumbra, Inc.$140
- plus $106 from 3 others
What the payments were for
- Travel & lodging$2,97230%
- Food & beverage$5,79858%
- Education$1,20012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 61 | $4,855 |
| Integra Lifesciences Corporation | 22 | $2,278 |
| Treace Medical Concepts, Inc. | 12 | $1,234 |
| Rock Medical Orthopedics, Inc. | 2 | $1,213 |
| Core Surgical Group | 1 | $144 |
| Penumbra, Inc. | 1 | $140 |
| Smith+Nephew | 1 | $70 |
| Bioventus LLC | 1 | $22 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$3,590
- INTEGRA DERMAL REGENERATION TEMPLATE$1,197
- PRIMATRIX$1,197
- Lapiplasty System$942
- HOFFMANN$701
- SALVATION$575
- 1788$542
- ACell$417
- NEURAGEN$417
- ORTHOLOC 2 LAPIFUSE$277
- CITREFIX$270
- PROPHECY$253
- ORTHOLOC 3DI$245
- AUGMENT INJECTABLE$175
- PROSTEP MICA$168
- PROstep$168
- VALOR$168
- Penumbra System$140
- SPY-PHI SYSTEM$125
- ALLOGRAFT BIO-IMPLANTS$124
How this compares
$9,970 in reported general payments places this provider in the 70th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 11 | $309 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Austin
- Mark DaltonAustin$1.9M
- Andrew EbertAustin$82K
- Pedro CosculluelaAustin$69K
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.